Intravitreal triamcinolone acetonide for the management of diabetic papillopathy

Am J Ophthalmol. 2004 Jun;137(6):1151-3. doi: 10.1016/j.ajo.2004.01.032.


Purpose: To present a case of severe drop in vision in both eyes caused by diabetic papillopathy that was treated with an intravitreal injection of triamcinolone acetonide.

Design: Interventional case report.

Methods: A diabetic patient with bilateral diabetic papillopathy and drop in vision received sequential intravitreal triamcinolone acetonide injections to both eyes.

Results: Within 2 weeks of intravitreal injection, vision improved from counting fingers at 1 m to 20/50 OS, and from counting fingers at 4 m to 20/40 OD. This improvement was accompanied by resolution of disk swelling and macular edema. Vision remained stable in both eyes at 20/40 for 8 months of follow-up. No elevation of intraocular pressure beyond 21 mm Hg was noted at any time.

Conclusion: Diabetic papillopathy with severe drop in vision can be treated with intravitreal triamcinolone acetonide injection.

Publication types

  • Case Reports

MeSH terms

  • Diabetes Mellitus, Type 2 / complications
  • Diabetic Neuropathies / diagnosis
  • Diabetic Neuropathies / drug therapy*
  • Diabetic Neuropathies / etiology
  • Fluorescein Angiography
  • Glucocorticoids / therapeutic use*
  • Humans
  • Injections
  • Intraocular Pressure
  • Male
  • Middle Aged
  • Papilledema / diagnosis
  • Papilledema / drug therapy*
  • Papilledema / etiology
  • Triamcinolone Acetonide / therapeutic use*
  • Visual Acuity
  • Vitreous Body / drug effects


  • Glucocorticoids
  • Triamcinolone Acetonide